These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 11446525)

  • 41. Poor outcomes of empiric ceftriaxone ± azithromycin for community-acquired pneumonia caused by methicillin-susceptible Staphylococcus aureus.
    So W; Crandon JL; Nicolau DP
    Intern Emerg Med; 2016 Jun; 11(4):545-51. PubMed ID: 26531307
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A cost-minimisation analysis comparing moxifloxacin with levofloxacin plus ceftriaxone for the treatment of patients with community-acquired pneumonia in Germany: results from the MOTIV trial.
    Lloyd A; Holman A; Evers T
    Curr Med Res Opin; 2008 May; 24(5):1279-84. PubMed ID: 18358083
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Economic assessment of the community-acquired pneumonia intervention trial employing levofloxacin.
    Palmer CS; Zhan C; Elixhauser A; Halpern MT; Rance L; Feagan BG; Marrie TJ
    Clin Ther; 2000 Feb; 22(2):250-64. PubMed ID: 10743984
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outpatient management of community-acquired pneumonia.
    Froes F; Pereira JG; Póvoa P
    Curr Opin Pulm Med; 2019 May; 25(3):249-256. PubMed ID: 30585861
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe community-acquired pneumonia: validation of the Infectious Diseases Society of America/American Thoracic Society guidelines to predict an intensive care unit admission.
    Liapikou A; Ferrer M; Polverino E; Balasso V; Esperatti M; Piñer R; Mensa J; Luque N; Ewig S; Menendez R; Niederman MS; Torres A
    Clin Infect Dis; 2009 Feb; 48(4):377-85. PubMed ID: 19140759
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Summary of Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Disease Society and the Canadian Thoracic Society.
    Mandell LA; Marrie TJ; Grossman RF; Chow AW; Hyland RH; ;
    Can Respir J; 2000; 7(5):371-82. PubMed ID: 11058205
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gatifloxacin phase IV surveillance trial (TeqCES study) utilizing 5000 primary care physician practices: report of pathogens isolated and susceptibility patterns in community-acquired respiratory tract infections.
    Pfaller MA; Jones RN
    Diagn Microbiol Infect Dis; 2002 Sep; 44(1):77-84. PubMed ID: 12376036
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Improving outcomes in elderly patients with community-acquired pneumonia by adhering to national guidelines: Community-Acquired Pneumonia Organization International cohort study results.
    Arnold FW; LaJoie AS; Brock GN; Peyrani P; Rello J; Menéndez R; Lopardo G; Torres A; Rossi P; Ramirez JA;
    Arch Intern Med; 2009 Sep; 169(16):1515-24. PubMed ID: 19752410
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Community-acquired pneumonia.
    Polverino E; Torres Marti A
    Minerva Anestesiol; 2011 Feb; 77(2):196-211. PubMed ID: 21242952
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cost-effectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia.
    Paladino JA; Gudgel LD; Forrest A; Niederman MS
    Chest; 2002 Oct; 122(4):1271-9. PubMed ID: 12377852
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Patterns of initial antibiotic therapy for community-acquired pneumonia in U.S. hospitals, 2000 to 2009.
    Berger A; Edelsberg J; Oster G; Huang X; Weber DJ
    Am J Med Sci; 2014 May; 347(5):347-56. PubMed ID: 24029796
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Approaches to treatment of community-acquired pneumonia in the emergency department and the appropriate role of fluoroquinolones.
    Moran G
    J Emerg Med; 2006 May; 30(4):377-87. PubMed ID: 16740445
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of antimicrobial resistance on health outcomes in the out-patient treatment of adult community-acquired pneumonia: a probability model.
    Singer ME; Harding I; Jacobs MR; Jaffe DH
    J Antimicrob Chemother; 2003 May; 51(5):1269-82. PubMed ID: 12697646
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Community-acquired pneumonia and tuberculosis: differential diagnosis and the use of fluoroquinolones.
    Grossman RF; Hsueh PR; Gillespie SH; Blasi F
    Int J Infect Dis; 2014 Jan; 18():14-21. PubMed ID: 24211230
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Improved management of community-acquired pneumonia in the emergency department.
    Julián-Jiménez A; Palomo de los Reyes MJ; Parejo Miguez R; Laín-Terés N; Cuena-Boy R; Lozano-Ancín A
    Arch Bronconeumol; 2013 Jun; 49(6):230-40. PubMed ID: 23477946
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aetiology and treatment of community-acquired pneumonia in adults: an historical perspective.
    Fass RJ
    J Antimicrob Chemother; 1993 Jul; 32 Suppl A():17-27. PubMed ID: 8407696
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nursing home-acquired pneumonia: update on treatment options.
    Mylotte JM
    Drugs Aging; 2006; 23(5):377-90. PubMed ID: 16823991
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Community-acquired pneumonia.
    Brown PD; Lerner SA
    Lancet; 1998 Oct; 352(9136):1295-302. PubMed ID: 9788476
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Atypical pathogen infection in community-acquired pneumonia.
    Yu Y; Fei A
    Biosci Trends; 2016 Feb; 10(1):7-13. PubMed ID: 26961211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Community-acquired pneumonia in adults: initial antibiotic therapy.
    King DE; Pippin HJ
    Am Fam Physician; 1997 Aug; 56(2):544-50. PubMed ID: 9262534
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.